Question special

Thank you again so much Dr Rosenson, Dr Baum and Dr Pordy for joining us for this journal club! This was an interesting article to read.

I was curious about the rate of adverse events for the SC Evinacumab group -- the highest rate of adverse events was for the 300mg q2weeks dosage (82% compared to placebo 54%) vs 300mg (67%) or 450mg weekly (68%). Would you consider this an outlier?

Thank you!